RCA
REGN icon

Resonant Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Resonant Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Sell
495
-6
-1% -$4.08K 0.01% 409
2026
Q1 		$387K Buy
501
+69
+16% +$52.8K 0.02% 321
2025
Q4 		$333K Buy
432
+69
+19% +$46.9K 0.02% 319
2025
Q3 		$204K Buy
+363
New +$205K 0.01% 422
2024
Q4 		– Sell
-370
Closed -$389K – 363
2024
Q3 		$389K Buy
370
+22
+6% +$24.5K 0.03% 234
2024
Q2 		$366K Buy
348
+16
+5% +$15.5K 0.03% 235
2024
Q1 		$320K Buy
+332
New +$316K 0.03% 260

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Resonant Capital Advisors's REGN Position: Q2 2026 in Review

Resonant Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 1.2% in Q2 2026, selling an estimated $4.08K and leaving 495 shares worth $309K. The position accounts for 0.01% of the portfolio, ranked #409.

Resonant Capital Advisors first reported a position in REGN in Q1 2024 and has held it in 7 quarters since. The position peaked at $389K in Q3 2024. 634 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Resonant Capital Advisors held 495 shares of Regeneron Pharmaceuticals worth $309K as of Q2 2026.
  • Resonant Capital Advisors sold 6 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.08K.
  • Regeneron Pharmaceuticals made up 0.01% of Resonant Capital Advisors's portfolio in Q2 2026, its #409 holding.
  • Resonant Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Resonant Capital Advisors's Regeneron Pharmaceuticals position peaked at $389K in Q3 2024.
  • 634 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Resonant Capital Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.